Literature DB >> 7870887

Central alpha-2 adrenoceptors are responsible for a clonidine-induced cue in a rat drug discrimination paradigm.

S Jordan1, H C Jackson, D J Nutt, S L Handley.   

Abstract

Clonidine produces an interoceptive discriminative stimulus or "cue" in rat drug discrimination studies. This cue may be mediated by its alpha-2 adrenoceptor agonist properties and/or its affinity for the non-adrenoceptor imidazoline preferring receptor. Six rats were trained to respond differentially after receiving clonidine (0.02 mg kg-1, IP) or a saline vehicle. The alpha-2 adrenoceptor agonists clonidine, UK14, 304 and rilmenidine, which bind to the imidazoline preferring receptor, and guanabenz which does not, dose-dependently substituted for (i.e. > 80% total responding was clonidine associated) the clonidine-induced cue in doses up to 0.02, 0.16, 1.25 and 0.32 mg kg-1, respectively. Furthermore, the cue was blocked when clonidine was given in combination with 30-min pretreatments of the highly selective alpha-2 adrenoceptor antagonists RX811059 (2.5 mg kg-1) and fluparoxan (3 mg kg-1). Since the clonidine-induced cue was substituted for by guanabenz, which does not act at the imidazoline-preferring receptor, and antagonised by RX811059 and fluparoxan it appears to be mediated by alpha-2 adrenoceptors. Moreover, abolition of the clonidine-induced cue did not occur with the peripherally acting alpha-2 adrenoceptor antagonist L659, 066 suggesting it involves central as opposed to peripheral sites.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7870887     DOI: 10.1007/bf02246975

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  Discriminative stimuli produced by clonidine in spontaneously hypertensive rats: generalization to antihypertensive drugs with different mechanisms of action.

Authors:  H Lal; S Yaden
Journal:  J Pharmacol Exp Ther       Date:  1985-01       Impact factor: 4.030

2.  A multicenter double-blind comparative study of rilmenidine and clonidine in 333 hypertensive patients.

Authors:  J P Fillastre; B Letac; F Galinier; G Le Bihan; J Schwartz
Journal:  Am J Cardiol       Date:  1988-02-24       Impact factor: 2.778

3.  The effects of idazoxan and other alpha 2-adrenoceptor antagonists on food and water intake in the rat.

Authors:  H C Jackson; I J Griffin; D J Nutt
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

4.  A TRS-80-based system for the control of behavioral experiments.

Authors:  M W Emmett-Oglesby; D G Spencer; D E Arnoult
Journal:  Pharmacol Biochem Behav       Date:  1982-09       Impact factor: 3.533

Review 5.  Clonidine: new research in psychotropic drug pharmacology.

Authors:  S Fielding; H Lal
Journal:  Med Res Rev       Date:  1981       Impact factor: 12.944

6.  Rilmenidine selectivity for imidazoline receptors in human brain.

Authors:  G Bricca; M Dontenwill; A Molines; J Feldman; E Tibirica; A Belcourt; P Bousquet
Journal:  Eur J Pharmacol       Date:  1989-04-25       Impact factor: 4.432

7.  Discriminative stimuli produced by clonidine: an investigation of the possible relationship to adrenoceptor stimulation and hypotension.

Authors:  D A Bennett; H Lal
Journal:  J Pharmacol Exp Ther       Date:  1982-12       Impact factor: 4.030

8.  Rilmenidine lowers arterial pressure via imidazole receptors in brainstem C1 area.

Authors:  R E Gomez; P Ernsberger; G Feinland; D J Reis
Journal:  Eur J Pharmacol       Date:  1991-03-26       Impact factor: 4.432

9.  A peripherally acting alpha-2 adrenoceptor antagonist: L-659,066.

Authors:  B V Clineschmidt; D J Pettibone; V J Lotti; H B Hucker; B M Sweeney; D R Reiss; E V Lis; J R Huff; J Vacca
Journal:  J Pharmacol Exp Ther       Date:  1988-04       Impact factor: 4.030

10.  Cardiovascular and central nervous system effects of rilmenidine (S 3341) in rats.

Authors:  E Koenig-Berard; C Tierney; B Beau; G Delbarre; F Lhoste; C Labrid
Journal:  Am J Cardiol       Date:  1988-02-24       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.